高级检索
徐斯盛, 张惠斌, 周金培, 黄建军. 新型抗糖尿病药物的研究进展[J]. 中国药科大学学报, 2011, 42(2): 97-106.
引用本文: 徐斯盛, 张惠斌, 周金培, 黄建军. 新型抗糖尿病药物的研究进展[J]. 中国药科大学学报, 2011, 42(2): 97-106.
XU Si-sheng, ZHANG Hui-bin, ZHOU Jin-pei, HUANG Jian-jun. Advances of new antidiabetic drugs[J]. Journal of China Pharmaceutical University, 2011, 42(2): 97-106.
Citation: XU Si-sheng, ZHANG Hui-bin, ZHOU Jin-pei, HUANG Jian-jun. Advances of new antidiabetic drugs[J]. Journal of China Pharmaceutical University, 2011, 42(2): 97-106.

新型抗糖尿病药物的研究进展

Advances of new antidiabetic drugs

  • 摘要: 糖尿病是一种慢性代谢性疾病,其主要表现为高血糖及微血管并发症,是影响人类生活的重大疾病之一。随着对糖尿病发病机制的深入研究,糖尿病药物研究也从对传统机制的药物研究过渡到对具有新作用靶点和新作用机制的药物研究。其中一些药物已经上市或正处于临床研究阶段,如胰高血糖素样肽-1受体激动剂、二肽基肽酶-4抑制剂、G蛋白偶联受体119激动剂、钠-葡萄糖同向转运体-2抑制剂、11β-羟基固醇脱氢酶1抑制剂以及蛋白质酪氨酸磷酸酶抑制剂等。本文按作用靶点和机制分类对上述新型抗糖尿病药物进行了综述。

     

    Abstract: Diabetes mellitus,an epidemic metabolic disorder characterized by high blood glucose level associated with various microvascular complications,is one of the main causes of human suffering across the globe.With the advance of the pathogenesis of diabetic research,the study of anti-diabetic drugs has transformed from the traditional drugs to the current products with new targets and new mechanism.Some of these drugs are already marketed or still in clinical trials,e.g. GLP-1 activator,DPP-4 inhibitor,GPR119 activator,SGLT-2 inhibitor,11β-HSD1 inhibitor,PTP1B inhibitor and so on.In this article,the new antidiabetic drugs mentioned above are reviewed with regard to the therapeutic targets and mechanism.

     

/

返回文章
返回